GSK shingles vaccine is officially available

June 28th, according to GlaxoSmithKline, the shingles vaccine was officially launched in China for the prevention of shingles in adults aged 50 and over.Xin'an Lishe is a recombinant sub-unit advent vaccine, injected in two doses of muscle. It is one of the first batch of 48 overseas "clinically in urgent need of new drugs" that have been rapidly introduced in China, and is the only recombinant shingles vaccine that has been listed in China, effectively filling the gap in the field of herpes disease prevention in China and further expanding China's vaccine prevention system.It is reported that shingles is caused by chickenpox-shingles virus reactivation. Almost all adults 50 years and older have been infected with chickenpox-shingles virus and may be reactivated with age.Xu Jinhua, director of dermatology at Huashan Hospital affiliated with Fudan University, stressed: "In addition to herpes shingles that can appear on one side of the body, causing people to suffer from rash, the most common complication is nerve pain after shingles, which can lead to burns, electric shocks, stab-like pain, acute pain may be more than birth pain, chronic cancer pain, seriously affecting the quality of life, obviously disrupting patients' sleep, mood, affecting work and daily life, seriously can lead to mental disorders and depression." The pre-tract period of shingles without skin damage is only difficult to diagnose when pain, and the current treatment of shingles is limited, vaccination is an effective measure to prevent shingles. "is able to produce a strong and long-lasting immune response using chickenpox-shingles virus glycoprotein E (gE) and the patented adsimosive system AS01B. In clinical trials in 18 countries and regions around the world, Xin'an Lisse showed significant protective effects for shingles, effectively reducing the risk of shingles in people 50 years of age and older.Thomas Breuer, GSK's Senior Vice President and Chief Medical Officer for Global Vaccines, said, "Xin Anli can help people overcome the decline in immune function as they age. It's great to see this innovative vaccine available in China, helping the public reduce the burden of this painful disease. Dengpresident of the Beijing Municipal Preventive Medicine Association, said: "The risk of infectious diseases in the elderly is high, the burden of disease is heavy, recombined shingles vaccine specifically for the middle-aged and elderly groups of vaccines." Its rapid introduction and listing is of great significance for maintaining the health function of middle-aged and old people and improving the health level of middle-aged and old people. Qi Xin,vice president of GSK and general manager of prescription drugs and vaccines in China, said: "The rapid approval of Xin'an Lisi to the market fully reflects the importance China attaches to important new prevention and treatment programs. I believe that the arrival of Xin'an Lis fit will help to raise awareness of adult vaccination in our country and better meet the challenges of disease, so as to enhance the health literacy of the whole population. (Xinhua) --